Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• Developing effective therapies for solid tumors is hindered by the challenge of modeling rare, panresistant cancer cell subpopulations.
• Existing cell culture models often fail to adequately represent the complexity and adaptability of these aggressive cancer cells.

Purpose of the Study:

• To develop and validate an optimal model for human triple-negative breast cancer cells with panresistance.
• To evaluate the efficacy of various anticancer agents in eradicating these highly adaptable cancer cells.

Main Methods:

• Selected highly adaptable cancer cells based on survival through a metabolic challenge.
• Analyzed gene expression, including embryo-like patterns and amplification of the FTO gene.
• Assessed epithelial to mesenchymal transition markers (ZEB1 and GRHL2).
• Tested a variety of anticancer agents against the developed model.

Main Results:

• The modeled cancer cells exhibited embryo-like gene expression and FTO gene amplification.
• Evidence of increased epithelial to mesenchymal transition was observed (ZEB1 upregulation, GRHL2 downregulation).
• Metabolically adaptable cancer cells demonstrated efficient metastasis in previous studies.
• Anticancer agents showed varying efficacy, supporting the model's validity.

Conclusions:

• The developed model effectively represents realistic panresistance in cancer cells.
• This model can be utilized for the development of novel anticancer agents designed to overcome panresistance.
• Further research into targeting these adaptable cancer cell populations is warranted.